Regeneron

News

Sanofi claims EU okay for Dupixent in asthma

Sanofi and partner Regeneron have picked up an approval in Europe for Dupixent in asthma, unlocking an important new indication for the fast-growing biologic.

News

Cholesterol drug from Sanofi/Regeneron gains US CV risk redu...

Sanofi and Regeneron’s Praluent cholesterol drug has been approved in the US to help prevent cardiovascular events, a new indication that will help it compete with Amgen’s rival from the sa

News

Sanofi/Regeneron skin cancer drug among flurry of decisions ...

A new drug for advanced skin cancer and a long-lasting treatment for haemophilia A are among a group of new drugs that look set for the European market following backing from regulators.

News

Regeneron and Alnylam announce $1bn collaboration

Regeneron has signed a collaboration deal potentially worth $1 billion with RNAi experts Alnylam Pharmaceuticals, to develop and commercialise drugs targeting eye, central nervous system (C

News

Praluent approved to reduce CV risk in Europe

The European Commission has approved Sanofi and Regeneron’s Praluent for reducing cardiovascular risk in adults with established atherosclerotic CV disease (ASCVD), giving the drug another advan

News

Sanofi/Regeneron’s Dupixent shows more promise in nasal poly...

Sanofi and Regeneron’s attempts to make Dupixent into a blockbuster franchise have been boosted with more strong phase 3 results in patients with chronic rhinosinusitis with nasal polyps (CRSwNP

Sanofi claims EU okay for Dupixent in asthma

Cholesterol drug from Sanofi/Regeneron gains US CV risk redu...

Sanofi/Regeneron skin cancer drug among flurry of decisions ...

Regeneron and Alnylam announce $1bn collaboration

Praluent approved to reduce CV risk in Europe

Sanofi/Regeneron’s Dupixent shows more promise in nasal poly...

Ambrosia's sweet $100m round, and other biofinancings

Using AI-driven synthetic personas to take your insights fur...

Regeneron

Editor's Picks